Literature DB >> 29399406

Deep sequencing of the T cell receptor visualizes reconstitution of T cell immunity in mogamulizumab-treated adult T cell leukemia.

Takero Shindo1,2, Kazutaka Kitaura3, Hiroshi Ureshino1, Kazuharu Kamachi4, Masaharu Miyahara4, Kazuko Doi5, Tatsuro Watanabe6, Eisaburo Sueoka6,7, Tadasu Shin-I8, Ryuji Suzuki3,9, Shinya Kimura1.   

Abstract

Although the anti-CCR4 antibody mogamulizumab (moga) shows striking antitumor activity against adult T cell leukemia (ATL), it can also cause fatal immunological pathology such as severe skin rash and graft-versus-host disease, which might be attributed to depletion of CCR4+ regulatory T cells. We previously showed that next generation sequencing enables precise analysis of the T cell receptor (TCR) repertoire, and we here used the technique to reveal the immunological dynamics in moga-treated ATL patients. Treatment with moga resulted in remarkable reduction or elimination of clonal cells, and enhanced reconstitution of non-tumor polyclonal CD4+ T cells and oligoclonal CD8+ T cells. Interestingly, cutaneous T cells infiltrating moga-related skin rashes did not share the same major clones in peripheral blood, which minimizes the possibility of cross-reaction. Thus, deep sequencing of the TCR can reveal the immune reconstitution of moga-treated ATL and provides powerful insights into its mode of action.

Entities:  

Keywords:  T cell receptor; adult T cell leukemia; immune reconstitution; mogamulizumab; next generation sequencing

Year:  2017        PMID: 29399406      PMCID: PMC5790365          DOI: 10.1080/2162402X.2017.1405204

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  19 in total

1.  Analysis of engraftment, graft-versus-host disease, and immune recovery following unrelated donor cord blood transplantation.

Authors:  B G Thomson; K A Robertson; D Gowan; D Heilman; H E Broxmeyer; D Emanuel; P Kotylo; Z Brahmi; F O Smith
Journal:  Blood       Date:  2000-10-15       Impact factor: 22.113

2.  Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.

Authors:  Kazuhito Yamamoto; Atae Utsunomiya; Kensei Tobinai; Kunihiro Tsukasaki; Naokuni Uike; Kimiharu Uozumi; Kazunari Yamaguchi; Yasuaki Yamada; Shuichi Hanada; Kazuo Tamura; Shigeo Nakamura; Hiroshi Inagaki; Koichi Ohshima; Hitoshi Kiyoi; Takashi Ishida; Kouji Matsushima; Shiro Akinaga; Michinori Ogura; Masao Tomonaga; Ryuzo Ueda
Journal:  J Clin Oncol       Date:  2010-02-22       Impact factor: 44.544

3.  Impaired production of naive T lymphocytes in human T-cell leukemia virus type I-infected individuals: its implications in the immunodeficient state.

Authors:  T Sakai; K Nosaka; S Tamiya; S Koga; S Mita; M Uchino; H Mitsuya; M Matsuoka
Journal:  Blood       Date:  2001-05-15       Impact factor: 22.113

4.  Pretransplantation Anti-CCR4 Antibody Mogamulizumab Against Adult T-Cell Leukemia/Lymphoma Is Associated With Significantly Increased Risks of Severe and Corticosteroid-Refractory Graft-Versus-Host Disease, Nonrelapse Mortality, and Overall Mortality.

Authors:  Shigeo Fuji; Yoshitaka Inoue; Atae Utsunomiya; Yukiyoshi Moriuchi; Kaoru Uchimaru; Ilseung Choi; Eiichi Otsuka; Hideho Henzan; Koji Kato; Takeaki Tomoyose; Hisashi Yamamoto; Saiko Kurosawa; Ken-Ichi Matsuoka; Takuhiro Yamaguchi; Takahiro Fukuda
Journal:  J Clin Oncol       Date:  2016-08-09       Impact factor: 44.544

5.  Atypical adult T-cell leukemia-lymphoma: diverse clinical manifestations of adult T-cell leukemia-lymphoma.

Authors:  M Shimoyama; K Minato; K Tobinai; M Nagai; T Setoya; T Takenaka; K Ishihara; S Watanabe; H Hoshino; M Miwa; M Kinoshita; S Okabe; N Fukushima; N Inada
Journal:  Jpn J Clin Oncol       Date:  1983       Impact factor: 3.019

6.  Stevens-Johnson Syndrome associated with mogamulizumab treatment of adult T-cell leukemia / lymphoma.

Authors:  Takashi Ishida; Asahi Ito; Fumihiko Sato; Shigeru Kusumoto; Shinsuke Iida; Hiroshi Inagaki; Akimichi Morita; Shiro Akinaga; Ryuzo Ueda
Journal:  Cancer Sci       Date:  2013-03-10       Impact factor: 6.716

Review 7.  Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma.

Authors:  Kenji Ishitsuka; Kazuo Tamura
Journal:  Lancet Oncol       Date:  2014-10       Impact factor: 41.316

8.  Effector Regulatory T Cells Reflect the Equilibrium between Antitumor Immunity and Autoimmunity in Adult T-cell Leukemia.

Authors:  Hiroshi Ureshino; Takero Shindo; Hiroyoshi Nishikawa; Nobukazu Watanabe; Eri Watanabe; Natsuko Satoh; Kazutaka Kitaura; Hiroaki Kitamura; Kazuko Doi; Kotaro Nagase; Hiromi Kimura; Makoto Samukawa; Susumu Kusunoki; Masaharu Miyahara; Tadasu Shin-I; Ryuji Suzuki; Shimon Sakaguchi; Shinya Kimura
Journal:  Cancer Immunol Res       Date:  2016-05-23       Impact factor: 11.151

9.  Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study.

Authors:  Takashi Ishida; Tatsuro Jo; Shigeki Takemoto; Hitoshi Suzushima; Kimiharu Uozumi; Kazuhito Yamamoto; Naokuni Uike; Yoshio Saburi; Kisato Nosaka; Atae Utsunomiya; Kensei Tobinai; Hiroshi Fujiwara; Kenji Ishitsuka; Shinichiro Yoshida; Naoya Taira; Yukiyoshi Moriuchi; Kazunori Imada; Toshihiro Miyamoto; Shiro Akinaga; Masao Tomonaga; Ryuzo Ueda
Journal:  Br J Haematol       Date:  2015-03-02       Impact factor: 6.998

10.  Enhancement of anti-STLV-1/HTLV-1 immune responses through multimodal effects of anti-CCR4 antibody.

Authors:  Kenji Sugata; Jun-Ichirou Yasunaga; Michi Miura; Hirofumi Akari; Atae Utsunomiya; Kisato Nosaka; Yuko Watanabe; Hitoshi Suzushima; Ki-Ryang Koh; Masanori Nakagawa; Michinori Kohara; Masao Matsuoka
Journal:  Sci Rep       Date:  2016-06-02       Impact factor: 4.379

View more
  6 in total

1.  Immunotherapy and molecular role of T-cell in PD-1 antibody treated resectable lung cancer patients.

Authors:  Samaresh Sau; Arun K Iyer
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

2.  Robust CD8+ T-cell proliferation and diversification after mogamulizumab in patients with adult T-cell leukemia-lymphoma.

Authors:  Masato Saito; Toshihiko Ishii; Itaru Urakawa; Asuka Matsumoto; Ayako Masaki; Asahi Ito; Shigeru Kusumoto; Susumu Suzuki; Takeshi Takahashi; Akimichi Morita; Hiroshi Inagaki; Shinsuke Iida; Takashi Ishida
Journal:  Blood Adv       Date:  2020-05-26

3.  Epstein-Barr virus-related diffuse large B-cell lymphoma in mogamulizumab-treated adult T-cell leukemia with incomplete T-cell reconstitution.

Authors:  Kazuharu Kamachi; Takero Shindo; Masaharu Miyahara; Kazutaka Kitaura; Michiaki Akashi; Tadasu Shin-I; Ryuji Suzuki; Koichi Oshima; Shinya Kimura
Journal:  Int J Hematol       Date:  2018-10-27       Impact factor: 2.319

4.  Effective maintenance treatment with lenalidomide for a patient with aggressive adult T cell leukemia after chemotherapy.

Authors:  Satoko Oka; Kazuo Ono; Masaharu Nohgawa
Journal:  Leuk Res Rep       Date:  2019-04-13

Review 5.  Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology.

Authors:  Isaure Vanmeerbeek; Jenny Sprooten; Dirk De Ruysscher; Sabine Tejpar; Peter Vandenberghe; Jitka Fucikova; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi; Abhishek D Garg
Journal:  Oncoimmunology       Date:  2020-01-09       Impact factor: 8.110

Review 6.  T cell receptor repertoire analysis in HTLV-1-associated diseases.

Authors:  Annaliese Clauze; Yoshimi Enose-Akahata; Steven Jacobson
Journal:  Front Immunol       Date:  2022-09-15       Impact factor: 8.786

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.